Dr Mikhael speaks with ecancer at EHA 23 about a phase Ib study of isatuximab, a CD38 targeted therapy, in combination with pomalidomide and dexamethasone to treat relapsed multiple myeloma.

He outlines the dose selection, and highlights the shorter infusion time of isatuximab compared to other CD38 molecules.

Patients experienced a 65% response rate with PFS approaching 18 months, and Dr Mikhael introduces recruitment for further trials of the combination.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.